About Cronex
Cronex is a company based in Hwaseong (South Korea) founded in 2012. Cronex offers products and services including Feed Automatic Line, Ventilation System, and Partitions and Floor Materials. Cronex operates in a competitive market with competitors including GenOway, TransCure bioServices, InVivo Biosystems, PsychoGenics and PharmaLegacy Laboratories, among others.
- Headquarter Hwaseong, South Korea
- SectorsHealthcare
- Phone•••• ••••
- Website cronex.co.kr
- Legal Name Cronex Co., Ltd.
- Annual Revenue$4.08 M (USD)30.13as on Dec 31, 2025
- Net Profit-$1.79 M (USD)-56.15as on Dec 31, 2025
- EBITDA$1.05 M (USD)0as on Dec 31, 2025
Associated legal entities of Cronex
Cronex operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of Cronex
Cronex offers a comprehensive portfolio of products and services, including Feed Automatic Line, Ventilation System, and Partitions and Floor Materials.
Automated system for efficient pig feed distribution in farms.
Provides air circulation to maintain optimal farm environments.
Materials for organizing and securing pig farming spaces.
IPO & Listings of Cronex
Cronex is a publicly listed company on the KRX with ticker symbol 215570 in South Korea, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Dec 2015
- Listed onKRX: 215570
- Listed entityCronex Co., Ltd.
- Exchange sectorCommercial services
- ISINKR7215570003
- Share price600.00 KRW · 2026-10-08
- Market capitalisation3,996,090,603.00 KRW
- Volume (last session)2
Financials of Cronex
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 5.89B KRW | -2.58B KRW | 1.52B KRW |
| 2024 | 4.53B KRW | -1.65B KRW | -266.0M KRW |
| 2023 | 4.68B KRW | -1.37B KRW | 440.0M KRW |
| 2022 | 4.50B KRW | -2.90B KRW | -691.6M KRW |
| 2021 | 3.28B KRW | -2.28B KRW | -1.54B KRW |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for Cronex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Cronex
Cronex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenOway, TransCure bioServices, InVivo Biosystems, PsychoGenics and PharmaLegacy Laboratories, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genoway.com | 1999 | Lyon, France | $11.55M | – | Provider of transgenic rodent models and customized cell lines for preclinical development | |
| transcurebioservices.com | 2012 | Archamps, France | $3.58M | – | Humanized mouse models are developed for preclinical immune drug studies. | |
| invivobiosystems.com | 2019 | United States | $8.16M | – | Animal models are supplied for in-vivo analytical services. | |
| psychogenics.com | 1999 | Tarrytown, United States | – | 124 | Preclinical CRO services for CNS and orphan disorders are offered. | |
| pharmalegacy.com | 2008 | Shanghai, China | – | – | Preclinical CRO offering in vivo models and services for a wide range of therapeutic areas | |
| noblelifesci.com | 2010 | Woodbine, United States | $335,000 | – | Preclinical contract research organization offering standard GLP and non-GLP services | |
| explorabiolabs.com | 2004 | San Diego, United States | – | – | Discovery pharmacology and vivarium services are provided to biotech clients. | |
| zeclinics.com | 2013 | Barcelona, Spain | – | – | Zebrafish models for toxicity studies are developed by ZeClinics CRO. | |
| thezebrafishlab.com | 2015 | Noain, Spain | – | – | Zebrafish assays are utilized for preclinical and environmental evaluations. | |
| vivobio.com | 2004 | Hyderabad, India | – | 5 | CRO providing drug development, discovery and biologic research services |
Detailed competitors of Cronex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cronex
The website of Cronex (cronex.co.kr) receives about 3.7K visits a month.
- Monthly visits3.7K
▲ 23.9% vs previous month
Similar companies to Cronex
10 companies that operate in the same segment as Cronex (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cronex
Cronex was founded in 2012.
Cronex is headquartered in Hwaseong, South Korea. It is registered at Hwaseong, Gyeonggi Province, South Korea.
Annual revenue of Cronex is $4.08M as on Dec 31, 2025.
Cronex was founded in 2012 and is based in Hwaseong, South Korea. Operations focus on the biotechnology sector, where species such as mini pigs are manufactured for research purposes. Non-clinical assessment services are delivered to the medical industry, supporting the development of new medicines and medical devices. These activities are conducted as a contract research organization.
Cronex's top competitors include GenOway, PsychoGenics and PharmaLegacy Laboratories.
Cronex offers Feed Automatic Line, Ventilation System, and Partitions and Floor Materials.
Yes, Cronex is publicly traded on KRX under the ticker symbol 215570.
Cronex operates through ,.